Nancy Harrison

President
MSI Methylation Sciences Inc.

Nancy Harrison

As a biotechnology venture capitalist, a company founder and owner and an active board member, Ms. Harrison is one of the most experienced biotech financial people in the Canadian life sciences industry.

As a biotechnology venture capitalist, a company founder and owner and an active board member, Ms. Harrison is one of the most experienced biotech financial people in the Canadian life sciences industry. She was instrumental in Ventures West’s involvement in the life sciences sector and with companies such as Angiotech Pharmaceuticals, Inc., AnorMed, Inc, Caprion Pharmaceuticals Inc., Celator Technologies Inc., Alder Biopharmaceuticals, Xenon Pharmaceuticals Inc., Salmedix Inc., Sembiosys Genetics Inc. and many other biotechnology firms while with Ventures West. This achievement lead to her winning The Caldwell Partners 40 under 40 Award for outstanding young business professionals. Nancy has turned a passion for strategy and medical discovery towards her own business, cofounding MSI Methylation Sciences Inc.

In late 2008, Ms. Harrison co-founded MSI Methylation Sciences Inc. and took on the role of Chief Business Officer and more recently the President role. Her focus is the strategic building of the business through involvement with the technology (primary author on several patents), money raising, partnering and financial aspects of the company. MSI is a small firm (less than 10 employees) which has gone from a start-up to phase II trials in less than 4 years. MSI has raised over US$60 million to fund its development.

Prior to this, Nancy was Senior Vice President / Partner at Ventures West Management Inc. She joined the firm as an associate in 1993 and by 1997 had built a one of Canada’s most successful biotechnology investment practices in Canada. During her tenure with Ventures West, the life sciences portfolio grew from 0% of the overall investment portfolio to approximately 30% of investments. The firm grew from about $90 million under management to about $750 million under management in 8 historical funds. The life sciences team invested about 25% of this allocation with the US and 75% in Canada. Nancy participated in over 30 investments over her time at the firm and specialized in helping Canadian life sciences companies raise Series B rounds through accessing US venture capital funds.

Ms. Harrison has participated in numerous not for profits and association boards including;

  • Vice Chair - Life Sciences BC
  • Board Member - e@UBC
  • Advisor - I2 Fund BC Genome
  • Advisor - BCTIA HyperGrowth:Life Sciences
  • Reviewer - Genomic Canada Grants

October 2016

Date modified: